At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 35 enrolled
Drug / intervention
Quetiapine XR (Seroquel XR)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 3 Weeks Open Label Study to Evaluate the Efficacy in Agitation and Safety of Quetiapine Fumarate XR in Treatment of Patients With Acute Schizophrenia
In Brief
A Phase 4 clinical trial evaluating Quetiapine XR (Seroquel XR) for Schizophrenia. Completed, enrolled 35 participants across 2 sites.
Detailed Summary
The purpose of the study is to determine whether treatment with quetiapine XR (Seroquel XR) tablets for 3 weeks will improve their agitation when they have acute psychosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesMalaysia
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2009
Enrollment StartSep 2009
Primary CompletionMar 2010
Study CompletionApr 2010
TodayJul 2026
First PostedAug 7, 2009
Enrollment StartSep 1, 2009
Primary CompletionMar 1, 2010
Study CompletionApr 1, 2010
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 16.9 years ago
Interventions
Quetiapine XR (Seroquel XR)drug
Tablet, oral, once daily